The Potential Societal Cost Benefits of Improved Inhalation Technique With Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Symbicort® Turbuhaler® for the Management of Asthma and Chronic Obstructive Pulmonary Disease in Sweden.
作者信息
Lewis A, Blackney M, Torvinen S, Lindqvist F, Safioti G, Grundström J, Polyzoi M, Plich A
机构信息
Covance Inc., London, UK.
Teva Pharmaceuticals Europe B. V, Amsterdam, The Netherlands.
出版信息
Value Health. 2014 Nov;17(7):A598-9. doi: 10.1016/j.jval.2014.08.2070. Epub 2014 Oct 26.
PMID:27202062
Abstract
摘要
Zotero 插件